4,6-Dichloro-2-(propylthio)pyrimidin-5-amine

We are 4,6-Dichloro-2-(propylthio)pyrimidin-5-amine CAS:145783-15-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


Product Name: 4,6-Dichloro-2-(propylthio)pyrimidin-5-amine
Synonym: Intermediate of Ticagrelor; 5-Amino-4,6-dichloro-2-(propylthio)pyrimidine; 4,6-dichloro-2-(propylsulfanyl)-5-pyriMidinaMine
Cas No.: 145783-15-9
Formula: C7H9Cl2N3S
MW: 238.14
EINECS No.: 808-051-8

Density: 1.4±0.1 g/cm3
Boiling point: 334.0±37.0 °C at 760 mmHg
Melting point: N/A
Flash point: 155.8±26.5 °C
Refractive index: 1.615

HS Code: 2942000000

UN No.: 1759
Hazard class: 8 categories 
Packing level: Class III
 
Specification

Items of Analysis Standard of Analysis Test Results
Appearance Yellow to yellowish brown oily
matter or solid
Conforms
Single impurity ≤0.5% 0.17%
Total impurity ≤1.0% 0.28%
Water ≤0.5% 0.15%
Assay 98.0%-102.0% 99.75%
Conclusion Conforms to Factory Standard

 
Application
Intermediate of Ticagrelor.
 
Packaging
25 kg/barrel, can also be packaged according to customer requirements. 
 
Storage
Store in a cool, ventilated warehouse. 
Keep away from fire and heat. 
The temperature should not exceed 37 °C. 

4,6-Dichloro-2-(propylthio)pyrimidin-5-amine


Related News: The iLet is designed to function as three medical devices in one. It can be configured as an insulin-only bionic pancreas, a glucagon-only bionic pancreas, or a bihormonal bionic pancreas using insulin and glucagon.HC Blue 14 CAS:99788-75-7 China will use its national drug bulk-buy scheme to lower the price of drugs currently sold at higher prices compared with other markets, it said in an official statement.2-(4-nitrophenyl)ethanamine,hydrochloride CAS:29968-78-3 Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.Biphenyl-3-boronic acid CAS:5122-95-2 Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).

Related Products
Product Name
1-tert-butyl-4-(chloromethyl)benzene View Details
3-BAP2NA-B View Details
trimethyl benzene-1,3,5-tricarboxylate View Details
4-nitrobenzene-1,3-diamine,sulfuric acid manufacturer 4-Chlorophenyl Cyclopropyl Ketone manufacturer 4-(TRIFLUOROMETHYL)PHENYL ISOTHIOCYANATE manufacturer 1-(benzotriazol-1-yl)octan-1-one manufacturer 2,2-Difluoro-2-(fluorosulfonyl)acetic acid Cas:1717-59-5 manufacturer